Harmony Biosciences Holdings (HRMY)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 453,001 | 311,660 | 243,784 | 234,309 | 228,631 |
| Short-term investments | US$ in thousands | 14,185 | 41,800 | 79,331 | — | — |
| Total current liabilities | US$ in thousands | 175,082 | 163,781 | 78,884 | 53,775 | 134,539 |
| Cash ratio | 2.67 | 2.16 | 4.10 | 4.36 | 1.70 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($453,001K
+ $14,185K)
÷ $175,082K
= 2.67
The cash ratio of Harmony Biosciences Holdings has shown variability over the analyzed period. Starting at 1.70 on December 31, 2020, the ratio increased to 4.36 by December 31, 2021, indicating a significant improvement in the company's ability to cover its short-term obligations with cash and cash equivalents.
However, the ratio decreased slightly to 4.10 by the end of 2022, but still remained at a healthy level. By December 31, 2023, the cash ratio dropped to 2.16, suggesting a potential reduction in the company's liquidity position compared to the previous year.
In the most recent year, December 31, 2024, the ratio increased to 2.67, indicating a slight improvement in Harmony Biosciences Holdings' ability to cover its short-term liabilities with its available cash resources. Overall, the company has maintained relatively strong liquidity levels throughout the analyzed period, with fluctuations observed from year to year.
Peer comparison
Dec 31, 2024